Stocktoria
Sarepta Therapeutics, Inc. SRPT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1997-06-04
Sarepta Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% |
| Net margin | -32.5% | 12.4% | -43.1% | -75.4% | -59.7% |
| FCF margin | -14.0% | -18.0% | -46.4% | -38.2% | -68.6% |
| Return on assets | -21.3% | 5.9% | -16.4% | -22.5% | -13.3% |
| Return on equity | -62.5% | 15.4% | -62.4% | -182.7% | -45.1% |
| Debt / equity | 0.73× | 0.74× | 1.44× | 4.01× | 0.61× |
| Current ratio | 2.32 | 4.20 | 3.95 | 4.13 | 5.75 |
| Revenue growth | 15.6% | 53.0% | 33.3% | 32.9% | 30.0% |
Source: SEC EDGAR filings · CIK 0000873303 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.